Liraglutide Prevents Post-Menopausal Weight and Fat Gain in Rats
Liraglutide prevented body weight gain, fat mass accumulation, and glucose intolerance in ovariectomized rats, a model for post-menopausal metabolic changes.
Quick Facts
What This Study Found
Liraglutide prevented body weight gain, fat mass accumulation, and glucose intolerance in ovariectomized rats, a model of post-menopausal metabolic changes.
Key Numbers
Ovariectomy led to increased body weight, adipose tissue mass, basal blood glucose, and impaired glucose tolerance. Liraglutide prevented these effects.
How They Did This
Animal study using Wistar rats — control group, ovariectomized group, and ovariectomized + liraglutide group.
Why This Research Matters
Many women gain significant weight during menopause due to declining estrogen. GLP-1 drugs might offer a targeted treatment option for this specific type of weight gain.
The Bigger Picture
Many women gain significant weight during menopause due to estrogen decline. GLP-1 drugs might offer a targeted treatment option for this specific type of metabolic deterioration, though human studies are needed.
What This Study Doesn't Tell Us
This is a rat study, and results may not directly translate to human menopause. Ovariectomy in young rats is not identical to natural menopause.
Questions This Raises
- ?Does liraglutide compensate for estrogen loss or work through independent mechanisms?
- ?Would this translate to human menopausal women?
Trust & Context
- Key Stat:
- All metabolic changes prevented Liraglutide blocked every measured metabolic consequence of ovariectomy: weight gain, fat accumulation, blood sugar rise, and glucose intolerance
- Evidence Grade:
- Rated preliminary: well-controlled animal study, but ovariectomy in young rats differs from natural human menopause.
- Study Age:
- Published in 2024. Contributes to growing interest in GLP-1 drugs for menopause-related metabolic issues.
- Original Title:
- Liraglutide prevents body and fat mass gain in ovariectomized Wistar rats.
- Published In:
- Molecular and cellular endocrinology, 594, 112374 (2024)
- Authors:
- Rossetti, Camila Lüdke, Andrade, Iris Soares, Fonte Boa, Luiz Fernando, Neves, Marcelo Barbosa, Fassarella, Larissa Brito, Bertasso, Iala Milene, Souza, Maria das Graças Coelho de, Bouskela, Eliete, Lisboa, Patrícia Cristina, Takyia, Christina Maeda, Trevenzoli, Isis Hara, Fortunato, Rodrigo Soares, Carvalho, Denise Pires de
- Database ID:
- RPEP-09172
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs help with menopausal weight gain?
In rats, liraglutide completely prevented the weight and metabolic changes from estrogen loss. Human studies in menopausal women are needed.
Why do women gain weight during menopause?
Declining estrogen levels reduce energy expenditure and increase fat storage, particularly in the abdomen. Insulin resistance also worsens.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09172APA
Rossetti, Camila Lüdke; Andrade, Iris Soares; Fonte Boa, Luiz Fernando; Neves, Marcelo Barbosa; Fassarella, Larissa Brito; Bertasso, Iala Milene; Souza, Maria das Graças Coelho de; Bouskela, Eliete; Lisboa, Patrícia Cristina; Takyia, Christina Maeda; Trevenzoli, Isis Hara; Fortunato, Rodrigo Soares; Carvalho, Denise Pires de. (2024). Liraglutide prevents body and fat mass gain in ovariectomized Wistar rats.. Molecular and cellular endocrinology, 594, 112374. https://doi.org/10.1016/j.mce.2024.112374
MLA
Rossetti, Camila Lüdke, et al. "Liraglutide prevents body and fat mass gain in ovariectomized Wistar rats.." Molecular and cellular endocrinology, 2024. https://doi.org/10.1016/j.mce.2024.112374
RethinkPeptides
RethinkPeptides Research Database. "Liraglutide prevents body and fat mass gain in ovariectomize..." RPEP-09172. Retrieved from https://rethinkpeptides.com/research/rossetti-2024-liraglutide-prevents-body-and
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.